Kisho is an information platform, not a medical provider. Nothing on this site constitutes medical advice, diagnosis, or treatment recommendations. All content is aggregated from publicly available sources (including ClinicalTrials.gov, PubMed, FDA.gov, and Orphanet) and is provided for informational purposes only. Clinical trial eligibility, treatment decisions, and any health-related actions should always be discussed with a qualified healthcare professional. Kisho does not endorse any specific therapy, organization, or clinical trial. Terms of use · Privacy policy
An uncommon, aggressive malignant smooth muscle neoplasm, usually occurring in post-menopausal women. It is characterized by a proliferation of neoplastic spindle cells. Morphologic variants include epithelioid, granular cell, inflammatory and myxoid leimyosarcomas.
Biomarker and diagnostic research for leiomyosarcoma has been reported in the published literature.
Estimated prevalence: Unknown (Unknown prevalence).
59 clinical trials registered, 34 recruiting. Interventions under study include drug therapy, procedural interventions, other interventions, and biologic therapy. Pipeline includes 3 PHASE3, 27 PHASE2, 13 PHASE1. Research is sponsored by a mix of industry and academic institutions.
NCT ID | Title | Phase | Sponsor | Status |
|---|---|---|---|---|
[NCT06849986](https://clinicaltrials.gov/study/NCT06849986) |
Data assembled from 4 of 12 sources · Last updated Sep 19, 2026, 6:01 AM UTC
Patient Advocacy Groups (PAGs) provide support, resources, and community for patients and caregivers.
European rare disease database
Genetic and Rare Diseases Info Center
IO Combined With AI as First-line Treatment for Patients With Soft Tissue Sarcoma(TAIS) |
PHASE2 |
Fudan University |
RECRUITING |
[NCT04031677](https://clinicaltrials.gov/study/NCT04031677) | Surgery With or Without Neoadjuvant Chemotherapy in High Risk RetroPeritoneal Sarcoma | PHASE3 | European Organisation for Research and Treatment of Cancer - EORTC | RECRUITING |
[NCT06571734](https://clinicaltrials.gov/study/NCT06571734) | XL092 (Zanzalintinib) for the Treatment of Patients With Metastatic or Unresectable Leiomyosarcoma, Bone Sarcoma or Translocation-associated Soft Tissue Sarcoma | PHASE2 | Northwestern University | RECRUITING |
[NCT04535271](https://clinicaltrials.gov/study/NCT04535271) | Metronomic Trabectedin, Gemcitabine, and Dacarbazine for Soft Tissue Sarcoma | PHASE2 | Sarcoma Oncology Research Center, LLC | RECRUITING |
[NCT05649956](https://clinicaltrials.gov/study/NCT05649956) | Letrozole in Uterine Leiomyosarcoma | PHASE2 | GOG Foundation | RECRUITING |
379 publications have been identified in PubMed for leiomyosarcoma. Kisho has analyzed 256 by research type. Research spans Case Report / Case Series (38%), Review / Meta-Analysis (17%), and Basic Science / Preclinical (13%).
Research Type | Count | % of Total |
|---|---|---|
Patient case studies | 96 | 38% |
Research summaries | 43 | 17% |
Laboratory research | 34 | 13% |
Clinical study results | 30 | 12% |
Disease patterns and progression | 24 | 9% |
Testing and diagnosis research | 20 | 8% |
New treatment approaches | 6 | 2% |
Other research | 3 | 1% |
Cong Q (2026). [PMID: 41557126](https://pubmed.ncbi.nlm.nih.gov/41557126/). *Discover oncology*. [Basic Science / Preclinical]
Nardi P (2026). [PMID: 41617455](https://pubmed.ncbi.nlm.nih.gov/41617455/). *Anticancer Res*. [Case Report / Case Series]
Jing CY (2026). [PMID: 41413787](https://pubmed.ncbi.nlm.nih.gov/41413787/). *J Gynecol Oncol*. [Diagnostic / Biomarker]
Ramdulari AV (2026). [PMID: 41910309](https://pubmed.ncbi.nlm.nih.gov/41910309/). *J Cancer Res Ther*. [Review / Meta-Analysis]
Denu RA (2026). [PMID: 42244620](https://pubmed.ncbi.nlm.nih.gov/42244620/). *bioRxiv*. [Basic Science / Preclinical]
Borella F (2026). [PMID: 41365077](https://pubmed.ncbi.nlm.nih.gov/41365077/). *Int J Gynecol Cancer*. [Review / Meta-Analysis]
Zhou FL (2026). [PMID: 42252304](https://pubmed.ncbi.nlm.nih.gov/42252304/). *Acta Pharmacol Sin*. [Basic Science / Preclinical]
Qi H (2026). [PMID: 42105786](https://pubmed.ncbi.nlm.nih.gov/42105786/). *J Immunol Res*. [Review / Meta-Analysis]
Choksi A (2026). [PMID: 41678049](https://pubmed.ncbi.nlm.nih.gov/41678049/). *Ann Surg Oncol*. [Case Report / Case Series]
Shalabaev B (2026). [PMID: 42262152](https://pubmed.ncbi.nlm.nih.gov/42262152/). *Oncotarget*. [Review / Meta-Analysis]
AI-curated news mentioning leiomyosarcoma
Updated Sep 10, 2026
A recent publication discusses the management strategies for soft tissue and visceral leiomyosarcomas, highlighting current treatment approaches and outcomes. This research contributes to the understanding of this rare cancer type.
A case study published in PubMed details metastatic leiomyosarcoma in an adult budgerigar, highlighting the disease's impact on bone and kidney. This research contributes to the understanding of leiomyosarcoma in avian species.
A case report highlights a rare collision tumor involving MMR deficient dedifferentiated endometrial carcinoma and synchronous uterine leiomyosarcoma. This study contributes to the understanding of these rare tumor types and their potential interactions.